Skip to main content


Figure 3 | Cardiovascular Diabetology

Figure 3

From: Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors

Figure 3

Measurement of diastolic function by echocardiography. Representative pulsed-wave Doppler images of Mitral valve flow of Control and STZ + Veh mice at 10 wks of diabetes (A and B, respectively). Temporal recordings of Mitral valve flow velocity (E/A) in control and diabetic mice implanted with saline minipumps (STZ + Veh), demonstrating development of diastolic dysfunction (C). Mitral valve flow velocity (D) and isovolumic relaxation time (E) of Control, STZ + Veh, and those treated with aliskiren (STZ + Alsk), benazeprilat (STZ + Benz), valsartan (STZ + Vals), and valsartan + PD123319 (STZ + Vals + PD); before STZ treatment and at 10 wks after becoming diabetic. 2 wk values for STZ + Vals + PD are shown, as we could not collect reliable (before STZ) data in this group. Values are expressed as the mean ± SEM. *P < 0.05 vs. Control (C) or respective Before STZ (D and E).

Back to article page